AntibioticDB

Development status: Active (as of 2022)

Combination therapy

Mechanism of Action/Target pathogen: Binds reversibly to beta-lactamases with a focus on class A enzymes, especially KPC enzymes. Fixed combination with meropenem

Additional information: Synthetic compound. 2019 approved in fixed combination with meropenem (Vabomere, Vaborem)

Source: https://pubmed.ncbi.nlm.nih.gov/25782055/

Citation (1): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985712/

Citation (2): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655098/

Citation (3): https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1756775

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/56649692

Vaborbactam, RPX7009

Beta-lactamase inhibitor (heterocyclic boron)

Rempex Pharmaceuticals, Melinta TherapeuticsMenarini

2013